Novartis Deploys New Antibody‑Specific AI Framework to Accelerate Therapeutic Drug Discovery

New AI Framework – A newly published antibody‑specific AI platform uses deep‑learning models trained on large public antibody databases to predict binding affinity, developability and stability, aiming to streamline the early phases of therapeutic drug design and reduce experimental iterations.

Novartis – Novartis announced it will pilot the framework within its antibody pipeline, integrating the predictions into its lead‑selection workflow and expecting to shorten candidate screening cycles, allowing faster progression to pre‑clinical studies and more efficient resource allocation.

Developers – A joint team of computational scientists at a biotech startup and immunology researchers at a university created the system, reporting validation on a benchmark set of 500 antibodies where the AI achieved higher predictive accuracy and identified novel candidates missed by conventional screening.

Pharma Industry – Faster antibody discovery using this AI tool could lower overall R&D expenditures by millions of dollars, shorten time to market for life‑saving therapies, and encourage other pharmaceutical companies to adopt similar machine‑learning approaches as part of their drug‑development strategies.